DOCSLIB.ORG

Prescribing Focus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prescribing Focus Prescribing Focus Geriatric RxMonitor Medication Appropriateness Evaluation (MAE) tool High risk medications in patients ≥ 65 years Drug Class Generic Drug Name Clinical Rationale/Reasons Analgesic, Indomethacin Indomethacin carries a black box NSAID warning for increased risk of GI bleeds/ perforation (higher risk in patients ≥ 65) and cardiovascular events. Indomethacin has the most adverse effects of all NSAIDS. Consider other safer alternatives.1,2,3 Analgesic, Ketorolac Ketorolac carries a black box warning for NSAID increased risk of GI bleeds/perforation (higher risk in patients ≥ 65) and cardiovascular events. Consider other safer alternatives.1,2,3,4 Analgesic, Meperidine Meperidine is not recommended for use in opioid narcotic the elderly. Accumulation of its metabolite (normeperidine) is associated with neurotoxicity. Commonly used dosages are not effective as an oral analgesic. Consider other safer alternatives.1,3,5 Abbreviations: CAPS — capsules. CNS — central nervous system. CrCl — creatinine clearance. GI — gastrointestinal. HTN — hypertension. NSAID — non-steroidal anti-inflammatory drug. SIADH — syndrome of inappropriate anti-diuretic hormone. SSRI — selective serotonin reuptake inhibitor. TAB — tablet. TCA — tricyclic antidepressant. OptumRx | optumrx.com Geriatric RxMonitor Medication Appropriateness Evaluation (MAE) tool Drug Class Generic Drug Name Clinical Rationale/Reasons Analgesic, Pentazocine Pentazocine is a mixed opioid agonist- opioid narcotic antagonist with more CNS side effects (e.g., confusion, hallucinations) than other narcotics. Use in the elderly may cause falls/ fractures, dependency, and withdrawal. Consider other safer alternatives.1,2 Anti-anxiety Meprobamate Meprobamate is a highly addictive and sedating anxiolytic and is not recommended in patients ≥ 65 years. Consider other safer alternatives.1,6 Antibiotic Nitrofurantoin Nitrofurantoin is not recommended in elderly patients, who are more likely to have CrCl < 30mL/min, due to risk of pulmonary and hepatic toxicity and ineffective drug concentration in the urine. Consider other safer alternatives.1,3 Anti-parkinsonian Benztropine (oral) Benztropine and trihexyphenidyl are not agents Trihexyphenidyl recommended in the elderly due to the availability of other safer alternatives with less anticholinergic properties. Elderly patients are more susceptible to memory impairment, confusion, and hallucinations. Consider other safer alternatives.1,6 Antidepressants, SSRI Paroxetine Paroxetine has the greatest anticholinergic properties (e.g., dizziness, blurred vision) of all SSRIs. Consider other safer alternatives.1,7 Abbreviations: CAPS — capsules. CNS — central nervous system. CrCl — creatinine clearance. GI — gastrointestinal. HTN — hypertension. NSAID — non-steroidal anti-inflammatory drug. SIADH — syndrome of inappropriate anti-diuretic hormone. SSRI — selective serotonin reuptake inhibitor. TAB — tablet. TCA — tricyclic antidepressant. 2 OptumRx | optumrx.com Drug Class Generic Drug Name Clinical Rationale/Reasons Antidepressants, Amitriptyline Tricyclic antidepressants (TCAs) have tertiary TCAs Amoxapine severe anticholinergic adverse events (e.g., sedation, confusion, constipation) and Clomipramine can cause orthostatic hypotension. TCAs Desipramine are contraindicated in the acute recovery Imipramine period of a myocardial infarction. Consider Nortriptyline other safer alternatives.1,6 Protriptyline Trimipramine Antidepressants, Doxepin cap > 6 mg/day Doxepin has strong anticholinergic properties tertiary TCAs (e.g., sedation, confusion, constipation) and can cause orthostatic hypotension. If used, monitor sodium concentrations closely with dosage adjustments. Consider other safer alternatives.1,5 Antihistamines Bropheniramine Antihistamines have anticholinergic Carbinoxamine adverse events (e.g., sedation, dizziness, blurred vision) that are more susceptible in Chlorpheniramine patients ≥ 65 years. Consider other safer Clemastine alternatives.1,6,8 Cyproheptadine Dexbrompheniramine Dexchlorpheniramine Diphenhydramine Dimenhydrinate Doxylamine Hydroxyzine Meclizine Promethazine Tiprolidine Abbreviations: CAPS — capsules. CNS — central nervous system. CrCl — creatinine clearance. GI — gastrointestinal. HTN — hypertension. NSAID — non-steroidal anti-inflammatory drug. SIADH — syndrome of inappropriate anti-diuretic hormone. SSRI — selective serotonin reuptake inhibitor. TAB — tablet. TCA — tricyclic antidepressant. 3 Geriatric RxMonitor Medication Appropriateness Evaluation (MAE) tool Drug Class Generic Drug Name Clinical Rationale/Reasons Antispasmodics Atropine (excludes ophthalmic) Antispasmodics have strong anticholinergic Belladonna Alkaloids properties (e.g., sedation, dizziness, and blurred vision) and uncertain effectiveness. Clidinium-Chlordiazepoxide Elderly patients may be at risk for toxicity Dicyclomine due to reduced renal function. Consider Hyoscyamine other safer alternatives with better Propantheline efficacy.1,6 Scopolamine Antithrombotic Ticlopidine Ticlopidine has been demonstrated to cause life-threatening neutropenia or agranulocytosis. Consider other safer alternatives with better efficacy.1,3 Barbiturates Amobarbital Barbiturates are highly addictive, and can Butabarbital cause more side effects than other sedative/ hypnotics (especially in patients ≥ 65 years). Butalbital With low dosages, tolerance to sleep effects Mephobarbital and increased risk of physical dependence can Pentobarbital occur. Use should be avoided due to risk of Phenobarbital overdose unless if being used for seizures.1,3,5,9 Secobarbital Benzodiazepines, Alprazolam Benzodiazepines are not recommended short- and immediate- Estazolam for use in the elderly due to an increased acting risk of cognitive impairment, delirium, Lorazepam falls, fractures, and motor vehicle crashes. Oxazepam Consider other safer alternatives.1 Temazepam Triazolam Benzodiazepines, Clorazepate Elderly patients have decreased metabolism long-acting Chlordiazepoxide of long-acting benzodiazepines. Use of long-acting agents may increase the risk of Clonazepam falls and cognitive impairment.1 Diazepam Flurazepam Quazepam Abbreviations: CAPS — capsules. CNS — central nervous system. CrCl — creatinine clearance. GI — gastrointestinal. HTN — hypertension. NSAID — non-steroidal anti-inflammatory drug. SIADH — syndrome of inappropriate anti-diuretic hormone. SSRI — selective serotonin reuptake inhibitor. TAB — tablet. TCA — tricyclic antidepressant. 4 OptumRx | optumrx.com Drug Class Generic Drug Name Clinical Rationale/Reasons Cardiovascular, Clonidine Central alpha agonists are not recommended central alpha-1 Guanabenz for routine treatment of hypertension. blockers There is a high risk of CNS adverse effects, Guanfacine bradycardia, and orthostatic hypotension Methyldopa when used in the elderly. Avoid clonidine as a first-line antihypertensive. Consider other safer alternatives.1,3 Cardiovascular, Nifedipine immediate release Immediate-release nifedipine is not calcium channel recommended for the treatment of chronic blocker HTN. Side effects include hypotension and the risk of precipitating heart attack. Consider other safer alternatives.1,10 Cardiovascular, Digoxin tab > 0.125 mg Since digoxin is renally eliminated, older other patients have a higher risk for toxicity (GI side effects, confusion, agitation, delirium) due to declining renal function. Avoid as first-line therapy for heart failure or atrial fibrillation and doses exceeding 0.125 mg/ day if possible.1,6,11 Cardiovascular, Disopyramide As a potent negative ionotrope, other disopyramide may induce heart failure in older patients. Disopyramide also has strong anticholinergic properties and should be avoided as an antiarrhythmic, if possible.1,3,6 Cardiovascular, Reserpine tab > 0.1 mg/day Reserpine side effects include bradycardia, other orthostatic hypotension and a high risk of CNS adverse effects. Avoid use in the elderly for the routine treatment of hypertension and in doses higher than 0.1 mg/day.1,6 Abbreviations: CAPS — capsules. CNS — central nervous system. CrCl — creatinine clearance. GI — gastrointestinal. HTN — hypertension. NSAID — non-steroidal anti-inflammatory drug. SIADH — syndrome of inappropriate anti-diuretic hormone. SSRI — selective serotonin reuptake inhibitor. TAB — tablet. TCA — tricyclic antidepressant. 5 Geriatric RxMonitor Medication Appropriateness Evaluation (MAE) tool Drug Class Generic Drug Name Clinical Rationale/Reasons Endocrine system, Megestrol Megestrol increases the risk of thrombotic progestin events (e.g., thrombophlebitis, pulmonary embolism) and death in patients ≥ 65 years with reduced kidney excretion. Consider other safer alternatives.1,6 Endocrine system, Estrogens oral or transdermal In older women (65 years and older), estrogens (conjugated, esterified) estrogen therapy shows evidence of carcinogenic potential and lack of cardio protective effect and cognitive protection (with or without progesterone). Weigh the risks and benefits of use.1,12 Endocrine system, Dessicated thyroid Elderly patients may have underlying other cardiovascular instability; therefore, thyroid doses in this population should be titrated carefully. Consider other safer alternatives.1,3 Gastrointestinal, Dexlansoprazole Avoid scheduled use of proton-pump proton-pump Esomeprazole inhibitors for > 8 weeks without a inhibitors strong indication due to increased risk of Lansoprazole Clostridium difficile infection, bone loss and Omeprazole fractures. 1 Pantoprazole Hypnotics, Eszopiclone
Load more

Recommended publications
  • Multi-Drug Rapid Test Panel with Adulteration (Urine)
    6-mono-aceto-morphine in urine is 3-7 days. Multi-Drug Rapid Test Panel with 6-MAM 10 Adulteration (Urine) (6-MAM10) The Multi-Drug Rapid Test Panel yields a positive result when the concentration of (±) 3,4-Methylenedioxy- (±) 3,4-Methylenedioxy- benzodiazepines in urine exceeds detective level. Package Insert 500 Buprenorphine (BUP) Amphetamine(MDA500) Amphetamine Instruction Sheet for testing of any combination of the following drugs: Ethyl- β-D-Glucuronide(ETG500) Ethyl- β -D-Glucuronide 500 Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is ACE/AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/TCA/TML/K sold under the trade names Subutex™, Buprenex™, Temgesic™ and Suboxone™, which ET/OXY/COT/EDDP/FYL/K2/6-MAM/MDA/ETG/CLO/LSD/MPD/ZOL Ethyl- β-D-Glucuronide(ETG1,000) Ethyl- β -D-Glucuronide 1,000 contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Including Specimen Validity Tests (S.V.T.) for: Clonazepam(CLO 400) Clonazepam 400 Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a Oxidants/PCC, Specific Gravity, pH, Nitrite, Glutaraldehyde and Creatinine Clonazepam(CLO 150) Clonazepam 150 form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in identical substance to the drug normally used. In substitution therapy, Buprenorphine is as human urine. For healthcare professionals including professionals at point of care sites. Lysergic Acid Diethylamide (LSD) Lysergic Acid Diethylamide 20 effective as Methadone but demonstrates a lower level of physical dependence.
    [Show full text]
  • MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted
    MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List The agents listed below are the antihistamine/decongestant drug products listed in the Mississippi Medicaid Preferred Drug List (PDL). This is a cross-reference between the drug product name and its active ingredients to reference the antihistamine/decongestant portion of the PDL. For more information concerning the PDL, including non- preferred agents, the OTC formulary, and other specifics, please visit our website at www.medicaid.ms.gov. List Effective 07/16/10 Therapeutic Class Active Ingredients Preferred Non-Preferred ANTIHISTAMINES - 1ST GENERATION BROMPHENIRAMINE MALEATE BPM BROMAX BROMPHENIRAMINE MALEATE J-TAN PD BROMSPIRO LODRANE 24 LOHIST 12HR VAZOL BROMPHENIRAMINE TANNATE BROMPHENIRAMINE TANNATE J-TAN P-TEX BROMPHENIRAMINE/DIPHENHYDRAM ALA-HIST CARBINOXAMINE MALEATE CARBINOXAMINE MALEATE PALGIC CHLORPHENIRAMINE MALEATE CHLORPHENIRAMINE MALEATE CPM 12 CHLORPHENIRAMINE TANNATE ED CHLORPED ED-CHLOR-TAN MYCI CHLOR-TAN MYCI CHLORPED PEDIAPHYL TANAHIST-PD CLEMASTINE FUMARATE CLEMASTINE FUMARATE CYPROHEPTADINE HCL CYPROHEPTADINE HCL DEXCHLORPHENIRAMINE MALEATE DEXCHLORPHENIRAMINE MALEATE DIPHENHYDRAMINE HCL ALLERGY MEDICINE ALLERGY RELIEF BANOPHEN BENADRYL BENADRYL ALLERGY CHILDREN'S ALLERGY CHILDREN'S COLD & ALLERGY COMPLETE ALLERGY DIPHEDRYL DIPHENDRYL DIPHENHIST DIPHENHYDRAMINE HCL DYTUSS GENAHIST HYDRAMINE MEDI-PHEDRYL PHARBEDRYL Q-DRYL QUENALIN SILADRYL SILPHEN DIPHENHYDRAMINE TANNATE DIPHENMAX DOXYLAMINE SUCCINATE
    [Show full text]
  • 2-Bromopyridine Safety Data Sheet Jubilant Ingrevia Limited
    2-Bromopyridine Safety Data Sheet According to the federal final rule of hazard communication revised on 2012 (HazCom 2012) Date of Compilation : July 03 ’ 2019 Date of Revision : February 09 ’ 2021 Revision due date : January 2024 Revision Number : 01 Version Name : 0034Gj Ghs01 Div.3 sds 2-Bromopyridine Supersedes date : July 03 ’ 2019 Supersedes version : 0034Gj Ghs00 Div.3 sds 2-Bromopyridine Jubilant Ingrevia Limited Page 1 of 9 2-Bromopyridine Safety Data Sheet According to the federal final rule of hazard communication revised on 2012 (HazCom 2012) SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1. Product identifier PRODUCT NAME : 2-Bromopyridine CAS RN : 109-04-6 EC# : 203-641-6 SYNONYMS : 2-Pyridyl bromide, Pyridine, 2-bromo-, beta-Bromopyridine, o-Bromopyridine SYSTEMATIC NAME : 2-Bromopyridine, -Pyridine, 2-bromo- MOLECULAR FORMULA : C5H4BrN STRUCTURAL FORMULA N Br 1.2. Relevant identified uses of the substance or mixture and uses advised against 1.2.1. Relevant identified uses 2-Bromopyridine is used as an intermediate in the pharmaceutical industry for the manufacture of Atazanavir (an antiretroviral drug), Carbinoxamine, Chloropyramine, triprolidine (antihistamine drugs), Disopyramide Phosphate (an antiarrythmic drug), Mefloquine (antimalarial drug), Pipradrol (mild CNS stimulant) etc. Uses advised against: None 1.3. Details of the supplier of the safety data sheet Jubilant Ingrevia Limited REGISTERED & FACTORY OFFICE: Jubilant Ingrevia Limited Bhartiagram, Gajraula , District: Amroha, Uttar Pradesh-244223, India PHONE NO: +91-5924-252353 to 252360 Contact Department-Safety: Ext. 7424 , FAX NO : +91-5924-252352 HEAD OFFICE: Jubilant Ingrevia Limited, Plot 1-A, Sector 16-A,Institutional Area, Noida, Uttar Pradesh, 201301 - India T +91-120-4361000 - F +91-120-4234881 / 84 / 85 / 87 / 95 / 96 [email protected] -www.jubilantingrevia.com 1.4.
    [Show full text]
  • Product Information
    PRODUCT INFORMATION NAME OF THE MEDICINE POLARAMINE® (dexchlorpheniramine maleate) DESCRIPTION Polaramine (dexchlorpheniramine maleate) is the dextro-isomer of chlorpheniramine maleate. It is an antihistamine with anticholinergic properties Dexchlorpheniramine maleate (CAS no. 2438-32-6) is described chemically as (+)-2-[p- chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine maleate (1:1). It has the empirical formula of C16H19ClN2.C4H4O4 and the following structural formula: Dexchlorpheniramine maleate is a white, odourless, crystalline powder which in aqueous solution has a pH of between 4 and 5. It is freely soluble in water, soluble in alcohol and in chloroform, but only slightly soluble in benzene or ether. PHARMACOLOGY Pharmacodynamics Mechanism of Action: Dexchlorpheniramine, the d-isomer of the racemic compound chlorpheniramine, is two times more active than chlorpheniramine. Dexchlorpheniramine does not prevent the release of histamine, but rather, competes with free histamine for binding at the H1-receptor sites, and competitively antagonizes the effects of histamine on H1-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Blockade of H1-receptors also suppresses the formation of oedema, flare, and pruritus that result from histaminic activity. Since dexchlorpheniramine binds to central and peripheral H1-receptors, sedative effects are likely to occur. H1-antagonists are structurally similar to anticholinergic agents and therefore possess the potential to exhibit anticholinergic properties of varying
    [Show full text]
  • Report Update 1
    Drug Class Review on Newer Antihistamines Final Report Update 1 April 2006 Original Report Date: November 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically (see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior version of this report can be accessed at the DERP website. Final Report Update #1 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION.............................................................................................................................................................4 SCOPE AND KEY QUESTIONS.............................................................................................................................6
    [Show full text]
  • Potentially Harmful Drugs in the Elderly: Beers List
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− March 2019 ~ Resource #350301 Potentially Harmful Drugs in the Elderly: Beers List In 1991, Dr. Mark Beers and colleagues published a methods paper describing the development of a consensus list of medicines considered to be inappropriate for long-term care facility residents.12 The “Beers list” is now in its sixth permutation.1 It is intended for use by clinicians in outpatient as well as inpatient settings (but not hospice or palliative care) to improve the care of patients 65 years of age and older.1 It includes medications that should generally be avoided in all elderly, used with caution, or used with caution or avoided in certain elderly.1 There is also a list of potentially harmful drug-drug interactions in seniors, as well as a list of medications that may need to be avoided or have their dosage reduced based on renal function.1 This information is not comprehensive; medications and interactions were chosen for inclusion based on potential harm in relation to benefit in the elderly, and availability of alternatives with a more favorable risk/benefit ratio.1 The criteria no longer address drugs to avoid in patients with seizures or insomnia because these concerns are not unique to the elderly.1 Another notable deletion is H2 blockers as a concern in dementia; evidence of cognitive impairment is weak, and long-term PPIs pose risks.1 Glimepiride has been added as a drug to avoid. Some drugs have been added with cautions (dextromethorphan/quinidine, trimethoprim/sulfamethoxazole), and some have had cautions added (rivaroxaban, tramadol, SNRIs).
    [Show full text]
  • Medication Instructions for Allergy Patients
    MEDICATION INSTRUCTIONS FOR ALLERGY PATIENTS Drugs which contain antihistamine or have antihistaminic effects can result in negative reactions to skin testing. As a result, it may not be possible to properly interpret skin test results, and testing may have to be repeated at a later date. While this list is extensive, it is NOT all inclusive (particularly of the various brand names). Discontinue ALL antihistamines including the following medications seven (7) days prior to skin testing (unless longer time specified): Antihistamines – Generic name (Brand name(s)): Cetirizine (Zyrtec, Zyrtec-D) Hydroxyzine (Vistaril, Atarax) Desloratadine (Clarinex) Levocetirizine (Xyzal) Fexofenadine (Allegra, Allegra-D) Loratadine (Claritin, Claritin-D, Alavert) Diphenhydramine (Aleve PM, Benadryl, Bayer P.M., Benylin, Contac P.M., Doans P.M, Excedrin PM, Legatrin P.M.. Nytol, Tylenol Nighttime, Unisom, Zzzquil) Chlorpheniramine (Aller-Chlor, Allerest, Alka Seltzer Plus, Chlor-Trimeton, Comtrex, Contac, Co-Pyronil, Coricidin, CTM, Deconamine, Dristan, Dura-tap, Naldecon, Ornade Spansules, Rondec, Sinutab, Teldrin, Triaminic, Triaminicin, Tylenol Allergy) Azatadine (Optimine, Trinalin) Doxylamine (Nyquil) Brompheniramine (Bromfed, Dimetane, Dimetapp) Meclizine (Antivert) Carbinoxamine (Clistin, Rondec) Pheniramine Clemastine (Tavist) Phenyltoloxamine (Nadecon) Cyclizine (Marezine) Promethazine (Phenergan) Cyprohepatidine (Periactin) (9 days) Pyrilamine (Mepyramine) Dexbrompheniramine (Drixoral) Quinacrine (Atabrine) Dexchlorpheniramine (Extendryl, Polaramine)
    [Show full text]
  • Randomized Controlled Pilot Trial of Cabergoline, Hydergine and Levodopa/Carbidopa: Los Angeles Cocaine Rapid Efficacy Screening
    Blackwell Science, LtdOxford, UKADDAddiction1359-6357© 2005 Society for the Study of Addiction 100•••• Original Article Cabergoline, hydergine, levodopa/carbidopa Steven Shoptaw et al. RESEARCH REPORT Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST) Steven Shoptaw1, Donnie W. Watson2, Chris Reiber1, Richard A. Rawson1, Margaret A. Montgomery3, Maria D. Majewska3 & Walter Ling1 UCLA Integrated Substance Abuse Programs, Los Angeles, CA1 , Friends Research Institute, Inc., Los Angeles, CA2 and National Institute on Drug Abuse, Division of Treatment Research and Development, Bethesda, MD, USA3 Correspondence to: ABSTRACT Steven Shoptaw PhD UCLA/Integrated Substance Abuse Programs Aim This study tested three dopaminergic medications against a common 11075 Santa Monica Blvd unmatched placebo condition: hydergine 1 mg three times daily (n = 15); Suite 200 levodopa/carbidopa 25/100 mg three times daily (n = 15); cabergoline 0.5 mg Los Angeles per week (n = 15); and placebo three times daily (n = 15) as potential pharma- CA 90025 USA cotherapies for cocaine dependence. E-mail: [email protected] Design The four-parallel group, Cocaine Rapid Efficacy Screening Trial (CREST) design featured a 2-week baseline period followed by randomization to an 8-week medication condition that included 1 hour per week of cognitive RESEARCH REPORT behavioral drug counseling. A safety evaluation was conducted 4 weeks after termination. Measures Outcomes included cocaine metabolites measured in urine, reten- tion and self-reports for drug use, cocaine craving, clinical improvement, mood and HIV risk behaviors. Results Participants assigned to receive cabergoline provided more urine sam- ples negative for cocaine metabolites (42.4%) than those assigned to receive pla- cebo (25.0%), a statistically significant difference after controlling for baseline differences in self-reported cocaine use (F = 2.95, df = 3; P = 0.05).
    [Show full text]
  • Full Prescribing Information for ANTIVERT®
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------WARNINGS AND PRECAUTIONS----------------------­ • May cause drowsiness: Use caution when driving a car or operating These highlights do not include all the information needed to use dangerous machinery (5.1). ANTIVERT® safely and effectively. See full prescribing information for ANTIVERT®. • Potential anticholinergic action: this drug should be prescribed with care to patients with a history of asthma, glaucoma, or enlargement of the prostate gland (5.2). ANTIVERT® (meclizine HCl) tablets, for oral use ANTIVERT® (meclizine HCl) chewable tablets, for oral use ------------------------------ADVERSE REACTIONS-------------------------------­ Initial U.S. Approval: 1957 Common adverse reactions are anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been ------------------------INDICATIONS AND USAGE-----------------------­ reported (6). ANTIVERT® is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults (1). To report SUSPECTED ADVERSE REACTIONS, contact Casper --------------------DOSAGE AND ADMINISTRATION------------------­ Pharma LLC at 1-844–5–CASPER (1-844-522-7737) or FDA at 1-800­ • Recommended dosage: 25 mg to 100 mg daily, in divided doses FDA-1088 or www.fda.gov/medwatch. (2.1). • Tablets: Swallow whole (2.2). --------------------------------DRUG INTERACTIONS-----------------------------­ • Chewable Tablets: Must be chewed or crushed before swallowing; do • Coadministration of ANTIVERT® with other CNS depressants, including not swallow whole (2.2). alcohol, may result in increased CNS depression (7.1). ------------------DOSAGE FORMS AND STRENGTHS-----------------­ • CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a • Tablets: 12.5 mg, 25 mg, and 50 mg (3). potential for drug-drug interactions between ANTIVERT® and CYP2D6 • Chewable Tablets: 25 mg (3). inhibitors (7.2).
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.
    [Show full text]
  • Chapter 34 • Drugs Used to Treat Nausea and Vomiting
    • Chapter 34 • Drugs Used to Treat Nausea and Vomiting • Learning Objectives • Compare the purposes of using antiemetic products • State the therapeutic classes of antiemetics • Discuss scheduling of antiemetics for maximum benefit • Nausea and Vomiting • Nausea : the sensation of abdominal discomfort that is intermittently accompanied by a desire to vomit • Vomiting (emesis): the forceful expulsion of gastric contents up the esophagus and out of the mouth • Regurgitation : the rising of gastric or esophageal contents to the pharynx as a result of stomach pressure • Common Causes of Nausea and Vomiting • Postoperative nausea and vomiting • Motion sickness • Pregnancy Hyperemesis gravidarum: a condition in pregnancy in which starvation, dehydration, and acidosis are superimposed on the vomiting syndrome • Common Causes of Nausea and Vomiting (cont’d) • Psychogenic vomiting: self-induced or involuntary vomiting in response to threatening or distasteful situations • Chemotherapy-induced emesis (CIE) Anticipatory nausea and vomiting: triggered by sight and smell associated with treatment Acute CIE: stimulated directly by chemotherapy 1 to 6 hours after treatment Delayed emesis: occurs 24 to 120 hours after treatment; may be induced by metabolic by-products of chemotherapy • Drug Therapy for Selected Causes of Nausea and Vomiting • Postoperative nausea and vomiting (PONV) • Antiemetics include: Dopamine antagonists Anticholinergic agents Serotonin antagonists H2 antagonists (cimetidine, ranitidine) • Nursing Process for Nausea and Vomiting
    [Show full text]
  • Uniform Classification Guidelines for Foreign Substances and Recommended Penalties Model Rule
    DRUG TESTING STANDARDS AND PRACTICES PROGRAM. Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. January, 2018 (V.13.4) Ó ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2018. Association of Racing Commissioners International 1510 Newtown Pike, Lexington, Kentucky, United States www.arci.com Page 1 of 61 Preamble to the Uniform Classification Guidelines of Foreign Substances The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991. "The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered.
    [Show full text]